Clay B Siegall became the president and CEO of Seattle Genetics, in which he found in 1988. He worked in several fields in the past such as Bristol Myers-Squibb Pharmaceutical research institute, National Cancer institute, National institutes of health and Alder BioPharmecuticals and Mirna Therapeutics.
Purpose/Goal of Company
It’s hard to imagine the physical and mental distress faced by cancer patients as they undergo chemotherapy. This occurs because chemotherapy targets normal, non-cancerous cells although they’re harmless. What if there’s a way that chemotherapy can destroy cancerous cells while leaving the regular ones unaffected? Seattle Genetics can solve this problem.
The company creates antibodies that can supplement chemo while only eliminating cancerous cells. These antibodies promotes anti-tumor activities and bypassess ordinary cells from being destroyed. As a result, hair-loss, tiredness from being anemic, bruises and sores that cancer patients face are reduced.
Several products are currently under development for effectiveness such as the SGN and ASN line of antibodies. ADCETRIS is currently used for relasped Hodgkin Lymphoma patients and it is currently available in the U.S an Canada.
The company hopes to commercialize and distribute their products to many hospitals and facilities. Their mission is a large effort to improve the quality of cancer treatment.
Mechanism of ADC Technology
The products created by Seattle Genetics involve an antibody-drug conjugate that is designed for a tumor associated antigen. The links that bind “Cytoxic” agents to the anti-body are released towards the antigen, destroying it. The anti-body gets inside of the cell by binding to an outside receptor. Once it’s inside of the cell, apoptosis occurs when the cytoxic agents are released. This also causes destruction of the anti-body.
Seattle genetics is pioneering a new stage of cancer treatment where patients are less damaged and have a better chance of survival. There’s little to know what potential these products have.